Patent ID: 11957660
Assignee: MITSUBISHI TANABE PHARMA CORPORATION
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 19:
20. An ALS therapeutic agent, comprising:
a drug product comprising edaravone and a thickening agent comprising at least one of tragacanth powder and xanthan gum,
wherein a dose of the drug product per one oral administration is in a range of 1 to 20 mL and contains the edaravone in a range of 50 to 210 mg, and the dose of the drug product per one oral administration does not contain a preservative selected from the group consisting of methylparaben, ethylparaben, propylparaben, butylparaben, benzoic acid, sorbic acid, sodium benzoate, benzyl alcohol, phenylethanol and a combination thereof, and does not have a bacterial growth for at least 28 days according to the preservation efficacy test of Japanese Pharmacopeia.